• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氟喹诺酮类药物对HERG电流的影响。

Effects of fluoroquinolones on HERG currents.

作者信息

Bischoff U, Schmidt C, Netzer R, Pongs O

机构信息

GENION Forschungsgesellschaft, Abteistrasse 57, 20149, Hamburg, Germany.

出版信息

Eur J Pharmacol. 2000 Oct 20;406(3):341-3. doi: 10.1016/s0014-2999(00)00693-2.

DOI:10.1016/s0014-2999(00)00693-2
PMID:11040340
Abstract

We have investigated the effects of four fluoroquinolones on the human ether-à-go-go-related gene (HERG) mediated K(+) currents to evaluate their potential to induce QT-prolongation. HERG currents were measured from stably transfected Chinese hamster ovary (CHO) cells by means of the patch-clamp technique. Bath application of sparfloxacin, moxifloxacin and grepafloxacin produced an inhibition of HERG outward currents at -40 mV with EC(50) of 13.5+/-0.8, 41. 2+/-2.0 and 37.5+/-3.3 microg/ml, respectively. Current inhibitions were reversible after washout of the compounds. By contrast, ciprofloxacin at concentrations of up to 100 microg/ml did not effect HERG outward currents.

摘要

我们研究了四种氟喹诺酮类药物对人醚 - 去极化相关基因(HERG)介导的钾离子电流的影响,以评估它们诱发QT间期延长的可能性。通过膜片钳技术,从稳定转染的中国仓鼠卵巢(CHO)细胞中测量HERG电流。浴槽给药司帕沙星、莫西沙星和格帕沙星可抑制 - 40 mV时的HERG外向电流,其半数有效浓度(EC50)分别为13.5±0.8、41.2±2.0和37.5±3.3 μg/ml。洗脱化合物后,电流抑制作用可逆。相比之下,浓度高达100 μg/ml的环丙沙星对HERG外向电流无影响。

相似文献

1
Effects of fluoroquinolones on HERG currents.氟喹诺酮类药物对HERG电流的影响。
Eur J Pharmacol. 2000 Oct 20;406(3):341-3. doi: 10.1016/s0014-2999(00)00693-2.
2
Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.一系列氟喹诺酮类抗菌药物与人类心脏钾通道HERG的相互作用。
Mol Pharmacol. 2001 Jan;59(1):122-6. doi: 10.1124/mol.59.1.122.
3
Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels.螺内酯及其主要代谢产物坎利酮可阻断人类醚 - 去极化相关基因通道。
Circulation. 2003 Feb 18;107(6):889-95. doi: 10.1161/01.cir.0000048189.58449.f7.
4
Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.1a类抗心律失常药物丙吡胺对HERG钾通道电流的抑制作用。
Biochem Biophys Res Commun. 2001 Feb 9;280(5):1243-50. doi: 10.1006/bbrc.2001.4269.
5
Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel.阿齐利特和安巴西利特对人ether-a-go-go相关基因(HERG)钾通道的比较作用。
Cardiovasc Res. 2000 Oct;48(1):44-58. doi: 10.1016/s0008-6363(00)00155-3.
6
Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline.丙咪嗪和阿米替林对异源表达的HERG钾通道电流的抑制作用。
Br J Pharmacol. 1999 Sep;128(2):479-85. doi: 10.1038/sj.bjp.0702800.
7
Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG.抗疟药物甲氟喹与人心脏钾通道KvLQT1/minK和HERG的相互作用。
J Pharmacol Exp Ther. 2001 Oct;299(1):290-6.
8
Modulation of HERG potassium channels by extracellular magnesium and quinidine.细胞外镁离子和奎尼丁对HERG钾通道的调节作用
J Cardiovasc Pharmacol. 1999 Feb;33(2):181-5. doi: 10.1097/00005344-199902000-00002.
9
Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization.坎地沙坦和依普罗沙坦对参与心脏复极化的人克隆钾通道的直接作用。
Mol Pharmacol. 2001 Apr;59(4):825-36. doi: 10.1124/mol.59.4.825.
10
Phospholipid metabolite 1-palmitoyl-lysophosphatidylcholine enhances human ether-a-go-go-related gene (HERG) K(+) channel function.磷脂代谢物1-棕榈酰溶血磷脂酰胆碱增强人醚-去极化相关基因(HERG)钾通道功能。
Circulation. 2001 Nov 27;104(22):2645-8. doi: 10.1161/hc4701.100513.

引用本文的文献

1
A randomized, double-blind, crossover study of the effect of the fluoroquinolone moxifloxacin on glucose levels and insulin sensitivity in young men and women.一项关于氟喹诺酮类药物莫西沙星对年轻男女性别血糖水平和胰岛素敏感性影响的随机、双盲、交叉研究。
Diabetes Obes Metab. 2023 Jan;25(1):98-109. doi: 10.1111/dom.14851. Epub 2022 Sep 12.
2
Use of Solvent Mapping for Characterizing the Binding Site and for Predicting the Inhibition of the Human Ether-á-Go-Go-Related K Channel.溶剂作图在人醚-α--go-go 相关钾通道的结合部位特征化和抑制预测中的应用。
Chem Res Toxicol. 2022 Aug 15;35(8):1359-1369. doi: 10.1021/acs.chemrestox.2c00036. Epub 2022 Jul 27.
3
Cardiac hERG K Channel as Safety and Pharmacological Target.
心脏 hERG K 通道作为安全性和药理学靶点。
Handb Exp Pharmacol. 2021;267:139-166. doi: 10.1007/164_2021_455.
4
Structures Illuminate Cardiac Ion Channel Functions in Health and in Long QT Syndrome.结构揭示健康及长QT综合征状态下的心脏离子通道功能
Front Pharmacol. 2020 May 4;11:550. doi: 10.3389/fphar.2020.00550. eCollection 2020.
5
Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.尖端扭转型室性心动过速和 QT 间期延长与抗生素的关联:美国 FDA 不良事件报告系统的药物警戒研究。
Int J Med Sci. 2019 Jun 10;16(7):1018-1022. doi: 10.7150/ijms.34141. eCollection 2019.
6
Molecular Docking Guided Grid-Independent Descriptor Analysis to Probe the Impact of Water Molecules on Conformational Changes of hERG Inhibitors in Drug Trapping Phenomenon.分子对接引导的网格独立描述符分析探究水分子对 hERG 抑制剂在药物捕获现象中构象变化的影响。
Int J Mol Sci. 2019 Jul 10;20(14):3385. doi: 10.3390/ijms20143385.
7
Asymmetry in catalysis by membrane-bound pyrophosphatase demonstrated by a nonphosphorus allosteric inhibitor.通过非磷变构抑制剂证明膜结合焦磷酸酶的催化不对称性。
Sci Adv. 2019 May 22;5(5):eaav7574. doi: 10.1126/sciadv.aav7574. eCollection 2019 May.
8
Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study.儿童患者单次静脉滴注莫西沙星的药代动力学、安全性和耐受性:1 期研究中的剂量优化。
J Clin Pharmacol. 2019 May;59(5):654-667. doi: 10.1002/jcph.1358. Epub 2019 Jan 25.
9
Experimentally Validated Pharmacoinformatics Approach to Predict hERG Inhibition Potential of New Chemical Entities.预测新化学实体hERG抑制潜力的实验验证药物信息学方法
Front Pharmacol. 2018 Sep 19;9:1035. doi: 10.3389/fphar.2018.01035. eCollection 2018.
10
Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin.迈向心脏毒性预测的转化鸿沟弥合:在莫西沙星 TdP 风险评估中应用渐进式心脏风险评估策略。
AAPS J. 2018 Mar 14;20(3):47. doi: 10.1208/s12248-018-0199-4.